<DOC>
	<DOC>NCT02921126</DOC>
	<brief_summary>To quantify rates of bleeding events and investigate the characteristics of prescribed patients, rates of bleeding events, persistence and healthcare resource utilization of Oral Anticoagulants (OACs) prescribed in routine clinical practice.</brief_summary>
	<brief_title>Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>are at least 18 years of age at index date Initiated new OAC therapy ( no previous prescriptions of the same index OAC in the last 12 months prior to the index date ) during the study period Had at least 1 claim with diagnosis of AF anytime in their records Have a record that is indicative of Valvular Atrial Fibrillation during this period Have a history of the OACs prescribed during the study period as assessed during the period of data availability(i.e. history of index OAC, as patients need to be newly prescribed either apixaban, rivaroxaban, dabigatran or VKA) Have more than one OAC exposure which starts on the same date</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>